Uveal melanoma (UM) represents the most common intraocular malignancy in adults and
accounts for about 5% of all melanomas. Primary disease can be effectively controlled by …

Background Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in
advanced stages. The value of the combined checkpoint blockade with CTLA-4 and PD-1 …

Background The use of immune checkpoint blockade (ICB) for uveal melanoma (UM) is little
established. The aim of this review was to provide a comprehensive overview on the …

Many therapies are being developed that use the patient's own immune response to treat
malignancies. One of the new types of immunotherapy is the application of monoclonal …

Uveal melanoma (UM) is the most common intraocular malignancy in adults and shows a
high rate of metastatic spread. As randomized clinical trials with immune checkpoint …

Background: Uveal melanoma is the most common primary intraocular malignancy among
adults. It is, nevertheless, a rare disease, with an incidence of approximately one case per …

Background Uveal melanoma (UM) is the most common intraocular malignancy in adults. In
contrast to cutaneous melanoma (CM), there is no standard therapy, and the efficacy and …

Background: Untreated metastatic uveal melanoma (UM) carries a grave prognosis. Unlike
cutaneous melanoma (CM), there are no established treatments known to significantly …

Background Uveal melanoma (UM) is an ocular malignancy with high potential for
metastatic spread. In contrast to cutaneous melanoma, immunotherapy has not yet shown …

Introduction Immune checkpoint inhibitor (ICI) based immunotherapy is dramatically
changing the management of many types of cancers including melanoma. In this …